3 assets in Male Reproductive System Neoplasm

Therapeutic assets addressing Male Reproductive System Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Male Reproductive System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Nivolumab Male Reproductive System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Vipivotide Tetraxetan Male Reproductive System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)